top of page

Dott. Dario Tumino

Medico esperto in ENDOCRINOLOGIA

University of Catania, Department of Clinical and Experimental Medicine 

Garibaldi Nesima Hospital, Via Palermo 636, Catania 

January 2019 - > 

PhD, University of Catania, Translational Biomedicine 

Garibaldi Nesima Hospital, Via Palermo 636, Catania 


August 2013-August 2018: 

Specialization in Endocrinology and Metabolism- 70/70 cum laude 

Thesis on: Surveillance of patients with differentiated thyroid cancer and indeterminate response 

Department of Clinical and Experimental Medicine - University of Catania 

March 2018 – May 2018 

Clinical Fellow 

University of Rome “La Sapienza”, Policlinico Umberto I, Dipartimento di Medicina Interna e Specialità mediche, Ambulatorio “Neoplasie tiroidee” under the guidance of Prof. S. Filetti and Tutor Prof. Cosimo Durante. 

1) Management of Nodular Thyroid Disease (diagnostic strategy, initial therapy, 

surveillance protocol) 

2) Thyroid and Neck Ultrasound 

3) Management of Advanced Thyroid Cancer 

January 2017-July 2017 

Clinical Fellow 

Thyroid Cancer Unit, under the guidance of Dr. Kate Newbold 

The Royal Marsden Hospital, London 

Focused on: 

1) Management of differentiated thyroid cancer from diagnosis to end of life (new and follow-up patients on clinical trials and those receiving systemic therapies such as kinase 

inhibitors; radioiodine ward rounds; external beam radiotherapy audit meetings) 

2) Management of patients undergoing systemic therapy for iodine refractory and for advanced medullary thyroid cancer. 

January 2017-July 2017 

Clinical Fellow 

Department on Diabetes and Endocrine, under the guidance of Dr. Daniel Morganstein 

Chelsea and Westminster Hospital, London 

Focused on: 

1) Endocrine Oncology including Endocrine cancers and Endocrine side effects of cancer immunotherapy. 

October 2006- July 2012: 

Degree in Medicine and Surgery – 110/110 cum laude 

Thesis on: Isolation and characterization of stem cells from thyroid cancer, under the supervision of Prof. F. Frasca – University of Catania 


1) Clinical aggressiveness and long-term outcome in patients with papillary thyroid 

cancer and circulating anti-thyroglobulin autoantibodies. Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Toteda M, Redler A, Ronga G, Filetti S, Monzani F; PTC Study Group. Thyroid. 2014 Jul;24(7):1139-45. doi: 10.1089/thy.2013.0698. Epub 2014 May 21. PubMed PMID: 24702238; PubMed Central PMCID: PMC4080868. 

2) Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. 

Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S; PTC Study Group. J Clin Endocrinol Metab. 2013 Feb;98(2):636-42. doi: 10.1210/jc.2012-3401. Epub 2013 Jan 4. PubMed PMID: 23293334. 

3) High prevalence of thyroid dysfunction in pregnant women. Altomare M, La Vignera S, 

Asero P, Recupero D, Condorelli RA, Scollo P, Gulisano A, Magro E, Tumino D, Tumino S, Vicari E, Leanza V, D'Agata R, Calogero AE. J Endocrinol Invest. 2013 Jun;36(6):407-11. doi: 10.3275/8658. Epub 2012 Oct 22. PubMed PMID: 23095459. 

4) Long-term surveillance of papillary thyroid cancer patients who do not undergo 

postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S; PTC Study Group. J Clin Endocrinol Metab. 2012 Aug;97(8):2748-53. Epub 2012 Jun 7. PubMed PMID: 22679061. 

5) Markers of semen inflammation – supplementary semen analysis? S. La Vignera, R. A. Condorelli, E. Vicari, D. Tumino , G. Morgia, V. Favilla*, S. Cimino*, A. E. Calogero, Journal of Reproductive Immunology 2013. Pubmed PMID: 23850173 

6) Metastatic malignant struma ovarii with coexistence of Hashimoto's thyroiditis. Russo 

M, Marturano I, Masucci R, Caruso M, Fornito MC, Tumino D, Tavarelli M, Squatrito S, Pellegriti G., Endocrinol Diabetes Metab Case Rep. 2016:160030. doi: 10.1530/EDM-16-0030. Epub 2016 May 21., PMID: 27224256 

7) Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory 

Differentiated Thyroid Cancer, D. Tumino, F. Frasca, K. Newbold, Front. Endocrinol., 20 November 2017 

8) Ruolo della 18FDG PET nel follow-up del carcinoma differenziato della tiroide (CDT) 

in presenza di valori di Tireoglobulina (Tg) indosabili, AAT elevati e TBS post-131-I negativo: esperienza clinica in una paziente. M. Tavarelli, G. Sapuppo, D. Tumino, R. Masucci, M. Russo, S. Squatrito, M. C. Fornito, G. Pellegriti. L’Endocrinologo. Springer International Publishing AG, part of Springer Nature 2018. 

9) Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature. K.A. Lee, M.T.A. Sharabiani, D. Tumino , J. Wadsley, V. Gill, G. Gerrard, R. Sindhu, M.N. Gaze, L. Moss, K. Newbold. Clinical Oncology 2019, 

10) Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments. G. Grani*, D. Tumino*, V. Ramundo, L. Ciotti, C. Lomonaco, M. Armillotta, R. Falcone, P. Lucia, M. Maranghi, S. Filetti, C. Durante. Journal of Endocrinological Investigation, published online 15 June 2019. *G. Grani and D. Tumino contributed equally. 

11) Surveillance of patients with differentiated thyroid cancer and indeterminate response: a 

longitudinal study on basal thyroglobulin trend. Malandrino P., Tumino D., Russo M., Marescalco S., Fulco R.A., Frasca F. J Endocrinol Invest. 2019 Oct;42(10):1223-1230. doi: 10.1007/s40618-019-01044-3. Epub 2019 Apr 8 

12) Nodular thyroid disease in the era of precision medicine. Dario Tumino, Giorgio Grani, 

Marta Di Stefano, Maria Di Mauro, Maria Scutari, Teresa Rago, Laura Fugazzola, Maria Grazia Castagna, Fabio Maino. Front. Endocrinol., 21 November 2019 



Translational research: 

1) Clinical pathological impacts of microRNAs in papillary thyroid carcinoma 

Clinical research: 

1) Endocrine Oncology 2) Thyroid Carcinoma 3) LT4/LT3 combined therapy 


1) Sub-investigator for the clinical trials (NCT02225509): “Clinical Validation of the 

Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis” 2) Sub-investigators for the clinical trials (NCT01876784): A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III study to assess the Efficacy and Safety of Vandetanib (CAPRELSATM; SAR390530 (formerly AstraZeneca ZD6474)) 300 mg in Patients with Differentiated Thyroid Cancer That Is either Locally Advanced or Metastatic who are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Principal investigator: Martin Schlumberger 3) European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib 

(CAPRELSATM) 300 mg in RET Mutation Negative and RET Mutation Positive Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (MTC) STUDY NUMBER: D4200C00104 (Sanofi- Genzyme OBS14778) 

4) Sub-investigators for the clinical trials: A Randomized, Double-Blind Study To Evaluate 

the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients 


1) SIE (Italian Society of Endocrinology) since 2013

2) EnGioI (Young Italian endocrinologists Society) since 2015

3) AIT (Associazione Italiana della tiroide) since 2016

4) ETA (European Thyroid Association) since 2017



1) Essential Good Clinical Practice (GPC) on 6 February 2017

2) University of Cambridge, Preliminary English Test (PET) on 17 July 2006 3) European Computer Driving Licence (ECDL) on 8 June 2004 

bottom of page